<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547556</url>
  </required_header>
  <id_info>
    <org_study_id>WP4b - adults</org_study_id>
    <nct_id>NCT04547556</nct_id>
  </id_info>
  <brief_title>ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms</brief_title>
  <acronym>ADEQUATE</acronym>
  <official_title>ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MJM Bonten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of rapid diagnostic testing of patients with Acute Respiratory Tract&#xD;
      Infection (ARTI) at the emergency department, on (1) hospital admission rates and (2)&#xD;
      antimicrobial prescriptions (days of treatment) and (3) the non-inferiority in terms of&#xD;
      clinical outcome. Geographical and seasonal variation will be assessed on a real time basis&#xD;
      including pathogens of public health interest. The impact will be stratified within age&#xD;
      groups and risk factors in order to determine the long-term clinical, public health and&#xD;
      economic determinants for the integration of diagnostics in a global and sustainable&#xD;
      perspective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive out of hospital (superiority endpoint)</measure>
    <time_frame>Day 1 - Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Days on Therapy (DOT) with antibiotics (superiority endpoint)</measure>
    <time_frame>Day 1 - Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse outcome (non-inferiority safety endpoint)</measure>
    <time_frame>Day 1 - Day 30</time_frame>
    <description>For initially non-admitted patients: any admission or death&#xD;
For initially hospitalized patients: any readmission, ICU admission &gt;= 24 hours after hospitalization, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Direct costs and indirect costs within 30 days after enrolment.</measure>
    <time_frame>Day 1 - Day 30</time_frame>
    <description>Cost of healthcare within 30 days after enrolment, including hospital and ICU days, utilisation of non-hospital services and cost of anti-infective and concomitant medication&#xD;
Cost of workdays lost within 30 days, including days for childcare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.</measure>
    <time_frame>Day 1, 14, 30</time_frame>
    <description>Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological results obtained as standard of care and with the diagnostic intervention</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of participants with an identified respiratory pathogen in both study groups on randomisation day samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empirical antibiotics based on antimicrobial agent categories</measure>
    <time_frame>Day 1 - Day 14</time_frame>
    <description>Proportion of participants on non-first-line anti-infective regimens (as defined by local guidelines)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic type switches and de-escalation based on antimicrobial agent categories</measure>
    <time_frame>Day 1 - Day 14</time_frame>
    <description>Time to de-escalation and time to stop of anti-infective therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of antimicrobial resistance (carriage or infection) related to the diagnostic intervention results compared to standard of care and impact on antimicrobial stewardship guidelines and prevention of hospital acquired infections.</measure>
    <time_frame>&gt;7 days after randomisation</time_frame>
    <description>Proportion of hospitalised participants with detection of cephalosporin-, carbapenem- or chinolone-resistant Enterobacteriaceae on any standard of care samples &gt;7 days after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on decisions regarding isolation measures related to test result.</measure>
    <time_frame>Day 1 - Day 30</time_frame>
    <description>Hours in individual or cohort isolation in hospitalised participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BioFire</intervention_name>
    <description>A molecular rapid syndromic testing platform, using the following panels:&#xD;
BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)&#xD;
BioFire FilmArray Pneumonia Panel plus (PP)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (≥18 years old) presenting to the Emergency Room with an acute illness (present&#xD;
             for 14 days or less) with cough, and with at least 1 other lower respiratory tract&#xD;
             symptom or clinical sign at physical examination:&#xD;
&#xD;
               -  Sputum production,&#xD;
&#xD;
               -  Breathlessness,&#xD;
&#xD;
               -  Chest discomfort or chest pain,&#xD;
&#xD;
               -  Wheeze,&#xD;
&#xD;
               -  Crackles,&#xD;
&#xD;
               -  Self-reported dystermia or documented fever;&#xD;
&#xD;
               -  Documented hypoxemia (adjusting definition for chronic oxygen therapy users,&#xD;
                  method of measurement) and no alternative explanation (infection, such as&#xD;
                  sinusitis; other, such as asthma).&#xD;
&#xD;
                  2. Managing medical team considers:&#xD;
&#xD;
                    1. to treat patient with antibiotics and/or to hospitalize patient&#xD;
&#xD;
                       AND&#xD;
&#xD;
                    2. that the rapid syndromic diagnostic test result can be awaited up to a&#xD;
                       maximum of 4 hours before the decision to discharge the patient or to&#xD;
                       initiate antibiotic therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Development of ARTI more than 48 hours after hospital admission (hospital acquired);&#xD;
&#xD;
          2. Patients with cystic fibrosis;&#xD;
&#xD;
          3. Less than 14 days since the last episode of respiratory tract infection;&#xD;
&#xD;
          4. Pregnancy (confirmed by pregnancy test) and breastfeeding;&#xD;
&#xD;
          5. Any clinically significant abnormality identified at the time of screening that in the&#xD;
             judgment of the Investigator would preclude safe completion of the study or constrain&#xD;
             endpoints assessment such as major systemic diseases or patients with short life&#xD;
             expectancy;&#xD;
&#xD;
          6. Inability to obtain informed consent from a competent patient.&#xD;
&#xD;
             Based on standard of care microbiological diagnosis and thoracic imaging (when&#xD;
             indicated):&#xD;
&#xD;
          7. Radiologically confirmed acute lobar pneumonia;&#xD;
&#xD;
          8. Known or suspected Pneumocystis jirovecii pneumonia or active tuberculosis;&#xD;
&#xD;
          9. Alternative noninfectious diagnosis that explains clinical symptoms (pulmonary&#xD;
             embolism, alveolar hemorrhage, acute heart failure, lung cancer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bonten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wietske Bouwman, MSc</last_name>
    <email>ADEQUATE@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupp, MD</last_name>
      <email>Jan.Rupp@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>MJM Bonten</investigator_full_name>
    <investigator_title>Professor Medical Microbiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

